Results 61 to 70 of about 692,682 (292)

Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015–2018)

Diabetes Care, 2020
BACKGROUND Lantus, the reference insulin glargine used for the treatment of diabetes, lost its patent protection in 2014, opening the market to biosimilar competitors.
I. Agirrezabal, E. Sánchez-Iriso, K. Mandar, J. Cabasés   +3 more
semanticscholar   +1 more source

Glargine as a Basal Insulin Supplement in Recovering Critically Ill Patients - An In Silico Study [PDF]

, 1993
Tight glycaemic control is now benefiting medical and surgical intensive care patients by reducing complications associated with hyperglycaemia. Once patients leave this intensive care environment, less acute wards do not continue to provide the same ...
Razak, N.N., Lin, J., Chase, J.G., Shaw, G.M., Pretty, C.G., Le Compte, A.J., Suhaimi, F.M., Jamaludin, U.   +7 more
core   +1 more source

Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults

Diabetes, 2019
β-Cell dysfunction is central to the pathogenesis of impaired glucose tolerance (IGT) and type 2 diabetes. Compared with adults, youth have hyperresponsive β-cells and their decline in β-cell function appears to be more rapid.

semanticscholar   +1 more source

Evidence review : liraglutide for the treatment of type 2 diabetes [PDF]

, 2011
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute
Cummins, E. (Ewen), HASH(0x5574f4171138), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +4 more
core  

When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]

, 2016
Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier, Cohen, Ohad, FILETTI, SEBASTIANO, Glandt, Mariela, MARANGHI, MARIANNA   +4 more
core   +2 more sources

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

Diabetes, obesity and metabolism, 2020
Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla‐300) and insulin degludec 100 U/mL (IDeg‐100 ...
M. Haluzík, A. Cheng, D. Müller-Wieland, J. Westerbacka, Z. Bosnyák, F. Lauand, Lydie Melas-Melt, J. Karalliedde, J. Rosenstock, G. Bolli   +9 more
semanticscholar   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes

Exploratory Research in Clinical and Social Pharmacy
Background: Treatment of type 1 diabetes requires insulin therapy, and various types of insulin can be used. Insulin glargine has been shown to provide effective glycemic control with reduced hypoglycemia.
Hiba Abdelmunim Suliman Elsheikh, Safaa Badi, Ahmed Hafiz Kamal, Mazen Karar, Mohamed Fouad, Omar Khalid, Omnia Abdullah, Setana Mamoun   +7 more
doaj   +1 more source

Clinical effectiveness and safety of analogue glargine in type 1 diabetes : systematic review and meta-analysis [PDF]

, 2016
INTRODUCTION: The use of insulin analogues for the treatment of type 1 diabetes mellitus (T1DM) is widespread; however, the therapeutic benefits still require further evaluation given their higher costs.
Acurico, Francisco A., Araujo, Vania E., Diniz, Leonardo M., Godman, Brian, Guerra Júnior, Augusto A., Marra, Lays P., Silva, Thales B. C., Álvares, Juliana   +7 more
core   +1 more source

Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26‐week, open‐label, multicentre study: The LixiLan JP‐O2 randomized clinical trial

Diabetes, obesity and metabolism, 2020
To assess efficacy and safety of 26‐week treatment with insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) compared with insulin glargine U100 (iGlar) in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on ...
Y. Terauchi, Takahiro Nakama, R. Spranger, A. Amano, T. Inoue, E. Niemoeller   +5 more
semanticscholar   +1 more source